The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo
The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency o...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2021-05, Vol.354, p.577544-577544, Article 577544 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 577544 |
|---|---|
| container_issue | |
| container_start_page | 577544 |
| container_title | Journal of neuroimmunology |
| container_volume | 354 |
| creator | Manouchehri, Navid Guisso, Dikran R. Hussain, Rehana Z. Minassian, Berge A. Stüve, Olaf |
| description | The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency of CD4high cells. However, the median florescent intensity (MFI) was not different. Initiation of in vivo pharmacotherapy or vehicle control was performed inC57BL/6 mice that were actively immunized for experimental autoimmune encephalomyelitis (EAE). In contrast to published reports, the mean frequency of CD4high cells, and the median fluorescent intensity (MFI) of CD4 was similar in both treatment groups. 25-day survival following active immunization among the MnTBAP treated animals compared to vehicle controls was16.6 ± 6.9 days vs 23.6 ± 2.7 days; (P value |
| doi_str_mv | 10.1016/j.jneuroim.2021.577544 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8109275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572821000710</els_id><sourcerecordid>33756414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-2aef28d3250f44eefb9808d7e622ba8ccb990c851447f1f2f9a496003ea5c3473</originalsourceid><addsrcrecordid>eNqFkM9O4zAQxi3ECkrhFZBfIF3bsWPngoCy_JFY7R7KhYvlOmNwldqVnYby9qQqRexpTzOa-b5vND-EzimZUEKrn4vJIsA6Rb-cMMLoREgpOD9AI6okKxRn9BCNBqEohGTqGJ3kvCCEipLXR-i4LKWoOOUj9Dx7BWxC5-PGN0PFv8Ps-uovbiJkHGKHwTmwne-hfR-GbyHBy7o1HeDpDcewWSXI2ceAfcAzbKFt87btfR9P0Q9n2gxnn3WMnm5_zab3xeOfu4fp1WNhOVVdwQw4ppqSCeI4B3DzWhHVSKgYmxtl7byuiVWCci4ddczVhtcVISUYYUsuyzG62OWu1vMlNBZCl0yrV8kvTXrX0Xj97yb4V_0Se60oqZkUQ0C1C7Ap5pzAfXkp0VvaeqH3tPWWtt7RHozn3y9_2fZ4B8HlTgDD_72HpLP1ECw0Pg1UdRP9_258ANlBllE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Manouchehri, Navid ; Guisso, Dikran R. ; Hussain, Rehana Z. ; Minassian, Berge A. ; Stüve, Olaf</creator><creatorcontrib>Manouchehri, Navid ; Guisso, Dikran R. ; Hussain, Rehana Z. ; Minassian, Berge A. ; Stüve, Olaf</creatorcontrib><description>The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency of CD4high cells. However, the median florescent intensity (MFI) was not different. Initiation of in vivo pharmacotherapy or vehicle control was performed inC57BL/6 mice that were actively immunized for experimental autoimmune encephalomyelitis (EAE). In contrast to published reports, the mean frequency of CD4high cells, and the median fluorescent intensity (MFI) of CD4 was similar in both treatment groups. 25-day survival following active immunization among the MnTBAP treated animals compared to vehicle controls was16.6 ± 6.9 days vs 23.6 ± 2.7 days; (P value <0.05). We conclude that MnTBAP (Sack and Herzog, 2009 (Sack and Herzog, 2009)) does not effectively downregulate CD4 expression in T cells in vivo, probably due to extensive mechanism that distinguishes it from an in vitro model (Harding, 1993 (Harding, 1993)) possesses toxic properties that may limit its clinic use in possible doses that could deliver the immunomodulation through down regulation of CD4 expression, and (Saizawa et al., 1987 (Saizawa et al., 1987)) has limited availability in specific tissues, including the CNS.
[Display omitted]</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2021.577544</identifier><identifier>PMID: 33756414</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animal models therapy ; CD4 MnTBAP ; Experimental autoimmune encephalomyelitis ; Multiple sclerosis</subject><ispartof>Journal of neuroimmunology, 2021-05, Vol.354, p.577544-577544, Article 577544</ispartof><rights>2021</rights><rights>Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c418t-2aef28d3250f44eefb9808d7e622ba8ccb990c851447f1f2f9a496003ea5c3473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2021.577544$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33756414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manouchehri, Navid</creatorcontrib><creatorcontrib>Guisso, Dikran R.</creatorcontrib><creatorcontrib>Hussain, Rehana Z.</creatorcontrib><creatorcontrib>Minassian, Berge A.</creatorcontrib><creatorcontrib>Stüve, Olaf</creatorcontrib><title>The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency of CD4high cells. However, the median florescent intensity (MFI) was not different. Initiation of in vivo pharmacotherapy or vehicle control was performed inC57BL/6 mice that were actively immunized for experimental autoimmune encephalomyelitis (EAE). In contrast to published reports, the mean frequency of CD4high cells, and the median fluorescent intensity (MFI) of CD4 was similar in both treatment groups. 25-day survival following active immunization among the MnTBAP treated animals compared to vehicle controls was16.6 ± 6.9 days vs 23.6 ± 2.7 days; (P value <0.05). We conclude that MnTBAP (Sack and Herzog, 2009 (Sack and Herzog, 2009)) does not effectively downregulate CD4 expression in T cells in vivo, probably due to extensive mechanism that distinguishes it from an in vitro model (Harding, 1993 (Harding, 1993)) possesses toxic properties that may limit its clinic use in possible doses that could deliver the immunomodulation through down regulation of CD4 expression, and (Saizawa et al., 1987 (Saizawa et al., 1987)) has limited availability in specific tissues, including the CNS.
[Display omitted]</description><subject>Animal models therapy</subject><subject>CD4 MnTBAP</subject><subject>Experimental autoimmune encephalomyelitis</subject><subject>Multiple sclerosis</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkM9O4zAQxi3ECkrhFZBfIF3bsWPngoCy_JFY7R7KhYvlOmNwldqVnYby9qQqRexpTzOa-b5vND-EzimZUEKrn4vJIsA6Rb-cMMLoREgpOD9AI6okKxRn9BCNBqEohGTqGJ3kvCCEipLXR-i4LKWoOOUj9Dx7BWxC5-PGN0PFv8Ps-uovbiJkHGKHwTmwne-hfR-GbyHBy7o1HeDpDcewWSXI2ceAfcAzbKFt87btfR9P0Q9n2gxnn3WMnm5_zab3xeOfu4fp1WNhOVVdwQw4ppqSCeI4B3DzWhHVSKgYmxtl7byuiVWCci4ddczVhtcVISUYYUsuyzG62OWu1vMlNBZCl0yrV8kvTXrX0Xj97yb4V_0Se60oqZkUQ0C1C7Ap5pzAfXkp0VvaeqH3tPWWtt7RHozn3y9_2fZ4B8HlTgDD_72HpLP1ECw0Pg1UdRP9_258ANlBllE</recordid><startdate>20210515</startdate><enddate>20210515</enddate><creator>Manouchehri, Navid</creator><creator>Guisso, Dikran R.</creator><creator>Hussain, Rehana Z.</creator><creator>Minassian, Berge A.</creator><creator>Stüve, Olaf</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20210515</creationdate><title>The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo</title><author>Manouchehri, Navid ; Guisso, Dikran R. ; Hussain, Rehana Z. ; Minassian, Berge A. ; Stüve, Olaf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-2aef28d3250f44eefb9808d7e622ba8ccb990c851447f1f2f9a496003ea5c3473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animal models therapy</topic><topic>CD4 MnTBAP</topic><topic>Experimental autoimmune encephalomyelitis</topic><topic>Multiple sclerosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manouchehri, Navid</creatorcontrib><creatorcontrib>Guisso, Dikran R.</creatorcontrib><creatorcontrib>Hussain, Rehana Z.</creatorcontrib><creatorcontrib>Minassian, Berge A.</creatorcontrib><creatorcontrib>Stüve, Olaf</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manouchehri, Navid</au><au>Guisso, Dikran R.</au><au>Hussain, Rehana Z.</au><au>Minassian, Berge A.</au><au>Stüve, Olaf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2021-05-15</date><risdate>2021</risdate><volume>354</volume><spage>577544</spage><epage>577544</epage><pages>577544-577544</pages><artnum>577544</artnum><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>The antioxidant MnTBAP was previously shown to down-regulate the surface expression of CD4 molecule in T cells. This observation obviously holds great potential impact in a number of pathological human conditions, including autoimmunity. Three different single doses of MnTBAP reduced the frequency of CD4high cells. However, the median florescent intensity (MFI) was not different. Initiation of in vivo pharmacotherapy or vehicle control was performed inC57BL/6 mice that were actively immunized for experimental autoimmune encephalomyelitis (EAE). In contrast to published reports, the mean frequency of CD4high cells, and the median fluorescent intensity (MFI) of CD4 was similar in both treatment groups. 25-day survival following active immunization among the MnTBAP treated animals compared to vehicle controls was16.6 ± 6.9 days vs 23.6 ± 2.7 days; (P value <0.05). We conclude that MnTBAP (Sack and Herzog, 2009 (Sack and Herzog, 2009)) does not effectively downregulate CD4 expression in T cells in vivo, probably due to extensive mechanism that distinguishes it from an in vitro model (Harding, 1993 (Harding, 1993)) possesses toxic properties that may limit its clinic use in possible doses that could deliver the immunomodulation through down regulation of CD4 expression, and (Saizawa et al., 1987 (Saizawa et al., 1987)) has limited availability in specific tissues, including the CNS.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33756414</pmid><doi>10.1016/j.jneuroim.2021.577544</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2021-05, Vol.354, p.577544-577544, Article 577544 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8109275 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
| subjects | Animal models therapy CD4 MnTBAP Experimental autoimmune encephalomyelitis Multiple sclerosis |
| title | The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A54%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20antioxidant%20MnTBAP%20does%20not%20effectively%20downregulate%20CD4%20expression%20in%20T%20cells%20in%20vivo&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Manouchehri,%20Navid&rft.date=2021-05-15&rft.volume=354&rft.spage=577544&rft.epage=577544&rft.pages=577544-577544&rft.artnum=577544&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2021.577544&rft_dat=%3Cpubmed_cross%3E33756414%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33756414&rft_els_id=S0165572821000710&rfr_iscdi=true |